's Docket No.: 10275-137001



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Michael D. Edge et al.

Art Unit

: 1632

Serial No.: 09/398,610

Examiner: J. Kerr

Filed

: September 17, 1999

Title

: TRANSGENICALLY PRODUCED FUSION PROTEINS

Commissioner for Patents Washington, D.C. 20231

REQUEST FOR CORRECTED OFFICIAL FILING RECEIPT

Please correct the Filing Receipt for the above-referenced application to change the last name of the first inventor from "EDGER" to "EDGE" and the first name of the third inventor from "CAYANN" to "YANN".

Please supply a corrected Filing Receipt to the undersigned with respect to this application. A copy of the original Filing Receipt showing the desired changes in red ink is attached for your convenience.

No fee is believed to be due. If, however, there are any charges or credits, please apply them to Deposit Account No. 06-1050.

Respectfully submitted.

Reg. No. 46,593

Fish & Richardson P.C. 225 Franklin Street

Boston, Massachusetts 02110-2804

Telephone: (617) 542-5070 Facsimile: (617) 542-8906

20371263.doc

CERTIFICATE OF MAILING BY FIRST CLASS MAIL I hereby certify under 37 CFR §1.8(a) that this correspondence is being deposited with the United States Postal Service as first class mail with sufficient postage on the date indicated below and is addressed to the Commissioner for Patents, Washington, D.C. 20231.

Date of Deposit

Typed or Printed Name of Person Signing Certificate





file:///c:/APPS/preexam/correspondence/1.htm

UNITED STATES DEPARTMENT OF COMMERCE Patent and Trademark Office

Address: ASSISTANT SECRETARY AND COMMISSIONER OF PATENT AND TRADEMARKS Washington, D.C. 20231

APPLICATION NUMBER FILING DATE **GRP ART UNIT** TOT FIL FEE REC'D ATTY.DOCKET.NO DRAWINGS IND CLAIMS CLAIMS 09/398.610 09/17/1999 1632 890 10275/137001 16 1

LOUIS MYERS FISH & RICHARDSON PC 225 FRANKLIN STREET BOSTON, MA 021102804

. APR 27.2000

Date Mailed: 04/10/2000

COPY OF PAPER. ORIGINALLY FILED

Receipt is acknowledged of this nonprovisional Patent Application. It will be considered in its order and you will be notified as to the results of the examination. Be sure to provide the U.S. APPLICATION NUMBER, FILING DATE, NAME OF APPLICANT, and TITLE OF INVENTION when inquiring about this application. Fees transmitted by check or draft are subject to collection. Please verify the accuracy of the data presented on this receipt. If an error is noted on this Filing Receipt, please write to the Office of Initial Patent Examination's Customer Service Center. Please provide a copy of this Filing Receipt with the changes noted thereon. If you received a "Notice to File Missing Parts" for this application, please submit any corrections to this Filing Receipt with your reply to the Notice. When the PTO processes the reply to the Notice, the PTO will generate another Filing Receipt incorporating the requested corrections (if appropriate).

Applicant(s)

EDGE

MICHAEL D. MACCLESFIELD, UNITED KINGDOM; DAN POLLOCK, MEDWAY, MA:

Yann

AMANGECHELARD, JAMAICA PLAIN, MA; HARRY M. MEADE, NEWTON, MA; SUSANNA M. RYBAK, FREDERICK, MD;

Continuing Data as Claimed by Applicant

THIS APPLN CLAIMS BENEFIT OF 60/101,083 09/18/1998

Foreign Applications

If Required, Foreign Filing License Granted 04/10/2000

Title

TRANSGENICALLY PRODUCED FUSION PROTEINS

Preliminary Class

800

RECEIVED

APR 1 3 2000

FISH & RICHARDSON, P.C. BOSTON OFFICE



6

OIPE Lata toptry by : DADE, JOAN

Team: OIPE

Date: 04/10/2000

T PROBLE BUILD TOUR THE FOUR BUILD B

LICENSE FOR FOREIGN FILING UNDER Title 35, United States Code, Section 184 Title 37, Code of Federal Regulations, 5.11 & 5.15

COPY OF PAPERS ORIGINALLY FILED

GRANTED

FEB -2 2 2002

The applicant has been granted a license under 35 U.S.C. 184, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" followed by a date appears on this form. Such licenses are issued in all applications where the conditions for issuance of a license have been met, regardless of whether or not a license may be required as set forth in 37 CRF 5.15. The scope and limitations of this license are set forth in 37 CFR 5.15(a) unless an earlier license has been issued under 37 CFR 5.15(b). The license is subject to revocation upon written notification. The date indicated is the effective date of the license, unless an earlier license of similar scope has been granted under 37 CFR 5.13 or 5.14.

This license is to be retained by the licensee and may be used at any time on or after the effective date thereof unless it is revoked. This license is automatically transferred to any related applications(s) filed under 36 CFR 1.53(d). This license is not retroactive.

The grant of a license does not in any way lessen the responsibility of a licensee for the security of the subject matter as imposed by any Government contract or the provisions of existing laws relating to espionage and the national security or the export of technical data. Licensees should apprise themselves of current regulations especially with respect to certain countries, of other agencies, particularly the Office of Defense Trade Controls, Department of State (with respect to Arms, Munitions and Implements of War (22 CFR 121-128)); the Office of Export Administration, Department of Commerce (15 CFR 370.10 (j)); the Office of Foreign Assets Control, Department of Treasury (31 CFR Parts'500+) and the Department of Energy.

NOT GRANTED

No license under 35 U.S.C. 184 has been granted at this time, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" DOES NOT appear on this form. Applicant may still petition for a license under 37 CFR 5.12, if a license is desired before the expiration of 6 months from the filing date of the application. If 6 months has lapsed from the filing date of this application and the licensee has not received any indication of a secrecy order under 35 U.S.C. 181, the licensee may foreign file the application pursuant to 37 CFR 5.15(b).

PLEASE NOTE the following information about the Filing Receipt:

- The articles such as "a," "an" and "the" are not included as the first words in the title of an application. They are considered to be unnecessary to the understanding of the title.
- The words "new," "improved," "improvements in" or "relating to" are not included as first words in the title of an application because a patent application, by nature, is a new idea or improvement.
- The title may be truncated if it consists of more than 600 characters (letters and spaces combined).
- The docket number allows a maximum of 25 characters.
- If your application was submitted under 37 CFR 1.10, your filing date should be the "date in" found on the Express Mail label. If there is a discrepancy, you should submit a request for a corrected Filing Receipt along with a copy of the Express Mail label showing the "date in."

Any corrections that may need to be done to your Filing Receipt should be directed to:

Assistant Commissioner for Patents Office of Initial Patent Examination Customer Service Center Washington, DC 20231 RECEIVED

MAR 1 3 2002

TECH CENTER 1600/2900